• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome.

作者信息

Hu Jianhua, Zhang Xiaoli, Zhang Xuan, Zhao Hong, Lian Jiangshan, Hao Shaorui, Jia Hongyu, Yang Meifang, Lu Yingfeng, Xiang Dairong, Cai Huan, Zhang Shanyan, Gu Jueqing, Ye Chanyuan, Yu Guodong, Jin Ciliang, Zheng Lin, Yang Yida, Sheng Jifang

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang, 310003, China.

出版信息

J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.056. Epub 2020 May 28.

DOI:10.1016/j.jinf.2020.05.056
PMID:32474032
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7255723/
Abstract
摘要

相似文献

1
COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome.高血压患者感染新型冠状病毒肺炎（COVID-19）病情更严重；血管紧张素转换酶抑制剂（ACEI）/血管紧张素Ⅱ受体阻滞剂（ARB）治疗不影响临床严重程度及预后。
J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.056. Epub 2020 May 28.
2
The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.新型冠状病毒病（COVID-19）的发生和严重程度与高血压患者使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂的关系。
PLoS One. 2021 Mar 18;16(3):e0248652. doi: 10.1371/journal.pone.0248652. eCollection 2021.
3
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.高血压合并 COVID-19 患者住院期间持续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与临床结局改善相关。
J Infect Dis. 2020 Sep 14;222(8):1256-1264. doi: 10.1093/infdis/jiaa447.
4
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.COVID-19 感染患者服用 ACEI/ARB 的结果。
Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4.
5
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.在 COVID-19 疫情背景下使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂：回顾性分析。
Front Med. 2020 Oct;14(5):601-612. doi: 10.1007/s11684-020-0800-y. Epub 2020 Jul 3.
6
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
7
Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study.高血压、药物治疗与重症 COVID-19 风险：一项基于马萨诸塞州社区的观察性研究。
J Clin Hypertens (Greenwich). 2021 Jan;23(1):21-27. doi: 10.1111/jch.14101. Epub 2020 Nov 21.
8
Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.肾素-血管紧张素系统抑制剂的使用对重症新冠肺炎合并高血压患者死亡率的影响：一项回顾性观察研究
J Int Med Res. 2020 Dec;48(12):300060520979151. doi: 10.1177/0300060520979151.
9
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体阻滞剂对 COVID-19 合并高血压患者的影响（COVIDECA 研究）。
Am J Cardiol. 2021 May 15;147:58-60. doi: 10.1016/j.amjcard.2021.02.009. Epub 2021 Feb 20.
10
Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.ACEi 和 ARB 在 COVID-19 管理中的安全性：回顾性分析。
Clin Cardiol. 2022 Jul;45(7):759-766. doi: 10.1002/clc.23836. Epub 2022 Apr 28.

引用本文的文献

1
Guillain-Barré syndrome (GBS) after severe/critical COVID-19 or COVID-19 vaccination.重症/危重症新型冠状病毒肺炎（COVID-19）或COVID-19疫苗接种后发生的吉兰-巴雷综合征（GBS）
Eur J Med Res. 2025 Feb 24;30(1):131. doi: 10.1186/s40001-025-02378-w.
2
The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.SARS-COV-2 变异株对疫苗接种和未完全接种疫苗患者的非呼吸道特征和死亡率的影响。
Vaccine. 2024 Apr 11;42(10):2655-2660. doi: 10.1016/j.vaccine.2024.02.036. Epub 2024 Mar 14.
3
Association between cardiovascular diseases and COVID-19 pneumonia outcome in Indonesia: a multi-center cohort study.
印度尼西亚心血管疾病与新冠肺炎肺炎结局之间的关联：一项多中心队列研究。
Front Med (Lausanne). 2023 Jun 29;10:1190148. doi: 10.3389/fmed.2023.1190148. eCollection 2023.
4
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.熊去氧胆酸对慢性肝病患者 COVID-19 的保护作用。
Front Cell Infect Microbiol. 2023 May 3;13:1178590. doi: 10.3389/fcimb.2023.1178590. eCollection 2023.
5
Total severity score and age predict long-term hospitalization in COVID-19 pneumonia.总严重程度评分和年龄可预测新冠肺炎肺炎患者的长期住院情况。
Front Med (Lausanne). 2023 Apr 12;10:1103701. doi: 10.3389/fmed.2023.1103701. eCollection 2023.
6
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.系统评价和荟萃分析 ACEI/ARB 在东亚 COVID-19 患者中的临床结局。
PLoS One. 2023 Jan 12;18(1):e0280280. doi: 10.1371/journal.pone.0280280. eCollection 2023.
7
Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients.新冠病毒肺炎患者的药物-疾病严重程度和靶疾病严重程度相互作用网络
Pharmaceutics. 2022 Aug 30;14(9):1828. doi: 10.3390/pharmaceutics14091828.
8
Drugs acting on the renin-angiotensin-aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies.作用于肾素-血管紧张素-醛固酮系统（RAAS）的药物与COVID-19患者死亡：观察性研究的系统评价和荟萃分析
Egypt Heart J. 2022 Sep 6;74(1):64. doi: 10.1186/s43044-022-00303-8.
9
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.高血压COVID-19患者长期使用肾素-血管紧张素-醛固酮抑制剂：一项西班牙登记研究和荟萃分析的结果
Med Clin (Engl Ed). 2022 Apr 8;158(7):315-323. doi: 10.1016/j.medcle.2021.04.026. Epub 2022 May 3.
10
The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review.不同类别抗高血压药物对新冠肺炎合并高血压患者的影响：一篇综述
Int J Hypertens. 2022 Jan 21;2022:5937802. doi: 10.1155/2022/5937802. eCollection 2022.